Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

Conference Correspondent  - Conference Correspondent, ASH

Chari and colleagues presented results of a 4-arm, open-label, multicenter, phase 1b study that evaluated the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab in combination with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.1 The study population (n = 98) had received a median of 4.0 (2-13) prior therapies; 98% of patients were refractory to bortezomib, 32% to carfilzomib, 89% to lenalidomide, and 67% to both a proteasome inhibitor and immunomodulatory drug. Of the 38 patients who discontinued study treatment, 19 (50%) were due to progressive disease and 8 (21%) were due to adverse events (AEs). Daratumumab-specific infusion-related reactions occurred in 52 patients, and included chills (14%), cough (11%), and dyspnea (11%). Grade 3/4 AEs were mostly hematologic, including neutropenia, anemia, leukopenia, and thrombocytopenia; nonhematologic grade 3/4 AEs included dyspnea, hypertension, and fatigue. Seventeen deaths were reported. In the 75 patients who had >1 postbaseline assessments, an overall response rate (ORR) of 53% was achieved, including 4 stringent complete responses, 3 complete responses, 25 very good partial responses, and 21 partial responses. Patients also achieved greater depth of response over time. In the cohort of patients with double-refractory disease, an ORR of 67% was achieved. The 6-month progression-free survival was 66%. Based on these results, the authors concluded that the addition of daratumumab to Pom/Dex resulted in high response rates, greater depth of responses, without unexpected or exacerbating known toxicities.

  1. Chari A, et al. ASH 2015. Abstract 508.
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017